Dongwon F&B, a subsidiary of Dongwon Industries, introduces a 100% plant-based canned ham, expanding their My Plant Original lineup and marking a significant stride in the vegetable protein movement.
Dongwon F&B said that through its latest plant-based ham product, it is gearing up to become a total protein provider, especially to vegetarians. Moreover, the company is launching this meat alternative while moving towards the popularization of vegetable-based protein options.
As per The Korea Times, Dongwon F&B said this is the company's third plant-based food item added to its My Plant brand. Previously, it created dumplings and tuna-flavored food without any meat ingredients. These were introduced in March this year.
The My Plant Original canned ham is 100% plant-based, meaning it was made with pure vegetable ingredients. It has no cholesterol and offers the lowest calories compared to rival products in the South Korean market.
Also, compared to Dongwon F&B's Richam luncheon meat, My Plant version's calories are less than 40%. With only 175kcal per 100 grams, it has the lowest calories among the domestic canned hams sold in the country.
"We are promoting various forms of collaboration with different companies based on our competitiveness in mass production infrastructure and independent technology for canned ham products," an official of Dongwon F&B said in a statement. "We will lead the popularization of meat alternatives by targeting overseas markets with our export infrastructure."
Korea's Daily Impact reported that to produce the My Plant Original meat alternative, Dongwon F&B combined technology and the know-how it accumulated in more than 20 years while producing its Recham ham products.
Finally, the company did not just manufacture a plain plant-based canned ham, but Dongwon F&B ensured the product also conforms to the healthy diet trend. With this said, My Plant Ham is perfect for health-conscious customers, too.
Photo by: Julia Fiander/Unsplash


SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
Locked up then locked out: how NZ’s bank rules make life for ex-prisoners even harder
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
Meta, U.S. States Discuss Settlement in Teen Addiction Trial
Yes, government influences wages – but not just in the way you might think
Want to cut your energy bills? Here’s how five experts are doing it
Heritage, desire and diplomacy: why China still values scotch whisky
Why a ‘rip-off’ degree might be worth the money after all – research study
Tesla Raises Cybertruck Prices by $5,000 in US
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny
The pandemic is still disrupting young people’s careers
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
What’s the difference between baking powder and baking soda? It’s subtle, but significant 



